Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 3, 2011, Pages 1599-1605

  Golbaz, Isabelle ^a   Ahlers, Christian ^a   Stock, Geraldine ^a   Schütze, Christopher ^a   Schriefl, Sabine ^a   Schlanitz, Ferdinand ^a   Simader, Christian ^a   Prünte, Christian ^a   Schmidt Erfurth, Ursula Margarethe ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VASCULOTROPIN ANTIBODY;

ADULT; ARTICLE; B SCAN; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG ACCUMULATION; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; INTRARETINAL EPITHELIUM; LOADING DRUG DOSE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECURRENT DISEASE; RETINA; RETINA MACULA AGE RELATED DEGENERATION; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBPIGMENT RETINAL EPITHELIUM; SUBRETINAL EPITHELIUM; SUBRETINAL FLUID; TIME; TREATMENT OUTCOME; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; EXUDATES AND TRANSUDATES; FOLLOW-UP STUDIES; HUMANS; IMAGING, THREE-DIMENSIONAL; INTRAVITREAL INJECTIONS; MIDDLE AGED; RETINA; RETINAL PIGMENT EPITHELIUM; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 79955933661     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-5018     Document Type: Article

References (19)

1. Shah AR, Del Priore LV. Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration. Ophthalmology. 2009;116:1901-1907.
2. Bolz M, Simader C, Ritter M, et al. Morphological and functional analysis of the loading regimen with intravitreal ranibizumab in neovascular AMD. Br J Ophthalmol. 2010;94:185-189.
3. Kaiser PK, Blodi BA, Shapiro H, Acharya NR. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:1868-1875.
4. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566-583.
5. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148:43-58, e41.
6. Cohen SY, Dubois L, Tadayoni R, et al. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol. 2009;148:409-413.
7. Ahlers C, Golbaz I, Stock G, et al. Time course of morphologic effects on different retinal compartments after ranibizumab therapy in age-related macular degeneration. Ophthalmology. 2008; 115:e39-e46.
8. Drexler W, Fujimoto JG. State-of-the-art retinal optical coherence tomography. Prog Retin Eye Res. 2008;27:45-88.
9. Pieroni CG, Witkin AJ, Ko TH, et al. Ultrahigh resolution optical coherence tomography in non-exudative age related macular degeneration. Br J Ophthalmol. 2006;90:191-197.
10. Schmidt-Erfurth U, Leitgeb RA, Michels S, et al. Three-dimensional ultrahigh-resolution optical coherence tomography of macular diseases. Invest Ophthalmol Vis Sci. 2005;46:3393-3402.
11. Hee MR, Baumal CR, Puliafito CA, et al. Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. Ophthalmology. 1996;103:1260-1270.
12. Srinivasan VJ, Wojtkowski M, Witkin AJ, et al. High-definition and 3-dimensional imaging of macular pathologies with high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology. 2006;113:2054 e2051-2014.
13. Sadda SR, Wu Z, Walsh AC, et al. Errors in retinal thickness measurements obtained by optical coherence tomography. Ophthalmology. 2006;113:285-293.
14. Leung CK, Chan WM, Chong KK, et al. Alignment artifacts in optical coherence tomography analyzed images. Ophthalmology. 2007;114:263-270.
15. Costa RA, Calucci D, Skaf M, et al. Optical coherence tomography 3: automatic delineation of the outer neural retinal boundary and its influence on retinal thickness measurements. Invest Ophthalmol Vis Sci. 2004;45:2399-2406.
16. Golbaz I, Ahlers C, Goesseringer N, et al. Automatic and manual segmentation of healthy retinas using high-definition optical coherence tomography. Acta Ophthalmol. In press.
17. Ahlers C, Golbaz I, Einwallner E, et al. Identification of optical density ratios in subretinal fluid as a clinically relevant biomarker in exudative macular disease. Invest Ophthalmol Vis Sci. 2009;50: 3417-3424.
18. Sadda SR, Keane PA, Ouyang Y, Updike JF, Walsh AC. Impact of scanning density on measurements from spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2010;51: 1071-1078.
19. Ritter M, Bolz M, Sacu S, et al. Effect of intravitreal ranibizumab in avascular pigment epithelial detachment. Eye (Lond). 2010;24: 962-968.